Subgroup outcomes from RAISE: A randomized, Phase 3 trial of zilucoplan in generalized myasthenia gravis

被引：0

作者：

Weiss, Michael D. ^{[1
]}

Bresch, Saskia ^{[2
]}

Freimer, Miriam ^{[3
]}

Hewamadduma, Channa ^{[4
]}

Juntas-Morales, Raul ^{[5
]}

Leite, M. Isabel ^{[6
]}

Maniaol, Angelina ^{[7
]}

Masuda, Masayuki ^{[8
]}

Sivakumar, Kumaraswamy ^{[9
]}

Zajda, Malgorzata ^{[10
]}

Boroojerdi, Babak ^{[11
]}

Duda, Petra W. ^{[12
]}

De La Borderie, Guillemette ^{[13
]}

Howard, James F., Jr. ^{[14
]}

机构：

[1] Univ Washington, Med Ctr, Dept Neurol, Seattle, WA USA

[2] Ctr Hosp Univ Nice, Nice, France

[3] Ohio State Univ, Columbus, OH USA

[4] Univ Sheffield, Dept Neurosci, Sheffield, S Yorkshire, England

[5] Vall dHebron Univ Hosp, Barcelona, Spain

[6] Univ Oxford, Nuffield Dept Clin Neurosci, Oxford, England

[7] Oslo Univ Hosp, Dept Neurol, Oslo, Norway

[8] Tokyo Med Univ, Dept Neurol, Tokyo, Japan

[9] Univ Arizona, Sch Med, Neuromuscular Clin & Res Ctr, Tucson, AZ USA

[10] Med Univ Warsaw, Warsaw, Poland

[11] UCB Pharma, Monheim, Germany

[12] UCB Pharma, Cambridge, MA USA

[13] UCB Pharma, Brussels, Belgium

[14] Univ N Carolina, Dept Neurol, Chapel Hill, NC USA

来源：

NEUROLOGY | 2023年 / 100卷 / 17期

关键词：

D O I：

10.1212/WNL.0000000000202904

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P1-5.006

引用

页数：5

共 50 条

[1] OUTCOMES FROM RAISE: A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, PHASE 3 TRIAL OF ZILUCOPLAN IN GENERALIZED MYASTHENIA GRAVIS
Howard, James F., Jr.
Genge, Angela
Hussain, Yessar
Kaminski, Henry J.
Mantegazza, Renato
Utsugisawa, Kimiaki
Vu, Tuan
Brock, Melissa
Boroojerdi, Babak
Vanderkelen, Mark
de la Borderie, Guillemette
Duda, PetraW
Leite, M. Isabel
MUSCLE & NERVE, 2022, 65 : S34 - S35
[2] EFFICACY AND SAFETY OF ZILUCOPLAN IN MYASTHENIA GRAVIS: RESPONDER ANALYSIS FROM THE RANDOMIZED PHASE 3 RAISE TRIAL
Vu, Tuan
Genge, Angela
Hussain, Yessar
Kaminski, Henry
Leite, Maria Isabel
Mantegazza, Renato
Utsugisawa, Kimiaki
Brock, Melissa
Boroojerdi, Babak
Vanderkelen, Mark
de la Borderie, Guillemette
Duda, Petra
Howard, James
MUSCLE & NERVE, 2022, 66 : S108 - S109
[3] Response to zilucoplan in the Phase 3 RAISE study in patients with generalised myasthenia gravis
Mantegazza, R.
Bresch, S.
Freimer, M.
Hewamadduma, C.
Leite, M.
Maniaol, A.
Schmidt, J.
Utsugisawa, K.
Vu, T.
Boroojerdi, B.
Lejdstrom, R. Beau
Duda, P.
Grimson, F.
Savic, N.
Howard, J., Jr.
EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 207 - 208
[4] Efficacy of Rozanolixizumab in Generalized Myasthenia Gravis: Subgroup Analyses from the Randomized Phase 3 MycarinG Study
Vu, Tuan
Druzdz, Artur
Grosskreutz, Julian
Habib, Ali A.
Kaminski, Henry J.
Mantegazza, Renato
Utsugisawa, Kimiaki
Vissing, John
Beau-Lejdstrom, Raphaelle
Boehnlein, Marion
Gasalla, Teresa
Grimson, Fiona
Tarancon, Thais
Bril, Vera
NEUROLOGY, 2023, 100 (17)
[5] EFFICACY OF ZILUCOPLAN IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS WITHOUT PRIOR IMMUNOGLOBULIN OR PLASMA EXCHANGE TREATMENT IN THE RAISE STUDY
Howard, James F., Jr.
Masuda, Masayuki
Boroojerdi, Babak
Grimson, Fiona
Utsugisawa, Kimiaki
MUSCLE & NERVE, 2024, 70 (03) : 547 - 547
[6] ROZANOLIXIZUMAB IN GENERALIZED MYASTHENIA GRAVIS: RESPONDER ANALYSES FROM THE RANDOMIZED PHASE 3 MYCARING STUDY
Bril, Vera
Druzdz, Artur
Grosskreutz, Julian
Habib, Ali
Mantegazza, Renato
Sacconi, Sabrina
Utsugisawa, Kimiaki
Vissing, John
Vu, Tuan
Boehnlein, Marion
Bozorg, Ali
Gayfieva, Maryam
Woltering, Franz
Kaminski, Henry
MUSCLE & NERVE, 2022, 66 : S112 - S112
[7] A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis
Pasnoor, Mamatha
He, Jianghua
Herbelin, Laura
Burns, Ted M.
Nations, Sharon
Bril, Vera
Wang, Annabel K.
Elsheikh, Bakri H.
Kissel, John T.
Saperstein, David
Shaibani, J. Aziz
Jackson, Carlayne
Swenson, Andrea
Howard, James F., Jr.
Goyal, Namita
David, William
Wicklund, Matthew
Pulley, Michael
Becker, Mara
Mozaffar, Tahseen
Benatar, Michael
Pazcuzzi, Robert
Simpson, Ericka
Rosenfeld, Jeffrey
Dimachkie, Mazen M.
Statland, Jeffrey M.
Barohn, Richard J.
NEUROLOGY, 2016, 87 (01) : 57 - 64
[8] MINIMAL CLINICALLY IMPORTANT DIFFERENCE IN MYASTHENIA GRAVIS: OUTCOMES FROM A RANDOMIZED TRIAL
Katzberg, Hans D.
Barnett, Carolina
Merkies, Ingemar S. J.
Bril, Vera
MUSCLE & NERVE, 2014, 49 (05) : 661 - 665
[9] Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study
Howard Jr, James F.
Bresch, Saskia
Genge, Angela
Hewamadduma, Channa
Hinton, John
Hussain, Yessar
Juntas-Morales, Raul
Kaminski, Henry J.
Maniaol, Angelina
Mantegazza, Renato
Masuda, Masayuki
Sivakumar, Kumaraswamy
Smilowski, Marek
Utsugisawa, Kimiaki
Vu, Tuan
Weiss, Michael
Zajda, Malgorzata
Boroojerdi, Babak
Brock, Melissa
de la Borderie, Guillemette
Duda, Petra W.
Lowcock, Romana
Vanderkelen, Mark
Leite, M. Isabel
LANCET NEUROLOGY, 2023, 22 (05): : 395 - 406
[10] LONG-TERM SAFETY AND EFFICACY OF ZILUCOPLAN IN GENERALIZED MYASTHENIA GRAVIS: 120-WEEK INTERIM ANALYSIS OF RAISE-XT
Howard, James F., Jr.
Freimer, Miriam
Genge, Angela
Hewamadduma, Channa
Hussain, Yessar
Maniaol, Angelina
Mantegazza, Renato
Utsugisawa, Kimiaki
Vu, Tuan
Weiss, Michael D.
Boroojerdi, Babak
Duda, Petra W.
Grimson, Fiona
Vanderkelen, Mark
Leite, M. Isabel
MUSCLE & NERVE, 2024, 70 (03) : 684 - 685

← 1 2 3 4 5 →